🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

HC Biopharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with HC Biopharma as lead sponsor. Synced 26 Sep 2026
9Current trials
8Recruiting now
11Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

HC Biopharma is the lead sponsor of 9 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are HC010, HC006 and HC022. The most-studied condition is Advanced Solid Tumor Cancer.

ClinicalTrials.gov trials by status

  • Recruiting889%
  • Not yet open111%

Trials by phase

  • Phase 1889%
  • Phase 2111%
01

Clinical trials sponsored by HC Biopharma

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer
Phase 1 Recruiting 2025-10 China
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
NCT06307925 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: HC010
Phase 1 Recruiting 2024-03 China
A Study of HC006 in Subjects With Advanced Solid Tumors
NCT06304571 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: HC006
Phase 1 Recruiting 2024-02 China
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
NCT06963814 · ClinicalTrials.gov ↗ · Advanced Cancer
Phase 1 Recruiting 2025-07 China
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
NCT06657703 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus
Drug: HC022
Phase 1 Recruiting 2024-11 China
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
NCT07813468 · ClinicalTrials.gov ↗ · Cetuximab, Bioequivalence, Healthy Volunteers
Phase 1 Recruiting 2026-09 China
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NCT07169552 · ClinicalTrials.gov ↗ · NSCLC
Drug: HC010
Phase 2 Recruiting 2025-12 China
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
NCT07477743 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer
Phase 1 Recruiting 2026-03 China
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Drug: HC022
Phase 1 Not yet open 2025-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in HC Biopharma trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in HC Biopharma trials

11 conditions
Advanced Solid Tumor Cancer2Advanced Solid Tumor2Advanced Cancer1Systemic Lupus Erythematosus1Systemic Lupus Erythematosus (SLE)1Cutaneous Lupus Erythematosus (CLE)1Cetuximab1Bioequivalence1Healthy Volunteers1Pharmacokinetics1NSCLC1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China98

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumor Cancer

SponsorTrials
Suzhou Genhouse Bio2
Calico Life Sciences1
LaNova Medicines1

Sponsors with the most current trials registered for this condition.

06

Questions about HC Biopharma trials

How many clinical trials does HC Biopharma sponsor?

HC Biopharma is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are HC Biopharma trials recruiting?

Yes. 8 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is HC Biopharma testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are HC010 (3), HC006 (2), HC022 (2), Cetuximab (1) and Docetaxel (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.